Crescendo Biologics develops targeted Humabody therapeutics that enhance T cell activation specifically within the tumor microenvironment, utilizing a proprietary transgenic mouse platform to create fully human VH domain building blocks. Their lead candidate, CB307, aims to provide prolonged anti-cancer effects in PSMA-positive solid tumors while minimizing systemic toxicity.
Funding
$32M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer immunotherapies often suffer from systemic toxicity due to broad T cell activation throughout the body, limiting their effectiveness and causing adverse side effects. This lack of tumor-specific targeting prevents optimal T cell engagement within the tumor microenvironment, hindering the ability to eradicate cancerous cells effectively.
Solution
Crescendo Biologics is developing Humabody therapeutics designed to enhance T cell activation specifically within the tumor microenvironment, thereby minimizing systemic toxicity. Their approach utilizes a proprietary transgenic mouse platform to generate fully human VH domain building blocks, enabling the creation of highly targeted immunotherapies. The lead candidate, CB307, is designed to provide prolonged anti-cancer effects in PSMA-positive solid tumors by selectively activating T cells in the presence of the PSMA target, while sparing healthy tissues. This targeted approach aims to improve the therapeutic window and reduce off-target effects commonly associated with traditional immunotherapies.
Target Audience
The primary target audience includes patients with PSMA-positive solid tumors, as well as pharmaceutical companies seeking novel, targeted immunotherapies with improved safety profiles.
Features
- Proprietary transgenic mouse platform for generating fully human VH domain building blocks (Humabodies)
- CB307: A Humabody bispecific designed to target PSMA-positive solid tumors and enhance T cell activation within the tumor microenvironment
- Focus on developing "2 in 1" immune cell engagers like CB699
- Preclinical data demonstrating tumor penetration capabilities of CB307
- Clinical biodistribution data for CB307 presented at ESMO 2024
- Zai Lab collaboration for global Phase 2 clinical trial evaluating ZL-1102 (Humabody, CB001) as a topical treatment for psoriasis